FDA: Factoring In Reimbursement, U.S. Bests Europe In Access To Innovative Devices
This article was originally published in The Gray Sheet
Executive Summary
FDA officials refute claims, frequently made by industry, that because FDA’s PMA review process is much slower than the CE mark regulatory process in Europe, Americans suffer delayed access to innovative and life-saving technology.
You may also be interested in...
Pre-Market Question Attracts Debate At EU Parliament Session On Device Reforms
The Committee held a workshop Feb. 26 to address a proposal issued last year by the European Commission to impose reforms on EU device oversight. Some members of Parliament and others in Europe believe the proposal may not go far enough when it comes to pre-market oversight.
FDA Will Not Broadly Release Report Criticizing EU Oversight
The agency decided not to widely disseminate a report examining 12 high-risk devices that were approved in Europe, but were later found to be dangerous or ineffective.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.